Dr. Jiazhi Sun focuses on Ras and ER signaling study, HDL-Receptor RNA alternative processing, and K-Ras, GPCR, BH3 protein and VDR/ER drug discovery targeting by utilizing Target-Guided Synthesis (TGS) approach and conventional intervention. Dr. Sun has more than 18-year professional experience in academic field including Drug Discovery, Signal Transduction, Apoptosis, Cancer Biology and Cardiovascular field, also leading collaborative Institutional and Pharmaceutical Industry rational design/targeted-therapeutic approach and development of FTI, GGTI and Kinase inhibitors (tyrosine, serine/threonine and sphingosine) and nuclear hormone receptor mimics as well as BH3-mimics as drug candidates and “Chemical-Genetics†tool/model. Since 1994, he has been involved in multiple programs yielding two U.S. patents, more than 30 peer-reviewed papers, book chapter, numerous awards including AFLAC Scholar in Cancer Research Award sponsored by American Association of Cancer Research and more than 30 scientific professional presentations.
